Wyeth enters three new R&D deals

Share this article:
Wyeth has inked three new collaboration agreements with separate biotech firms since the start of the new year, TheStreet.com reported. On Jan. 4 Wyeth signed an agreement with Pharmacopeia to develop products based on the Princeton, NJ’s research into the body’s immune system. Pharmacopeia said it hopes its research leads to treatments for rheumatoid arthritis and psoriasis. The deal could provide Pharmacopeia with up to $175 million in milestone payments, as well as sales-based royalties. Pharmacopeia, which has no commercial products, has also signed deals with Bristol-Myers Squibb and Schering Plough. Wyeth also agreed to join forces with Raven Biotechnologies of South San Francisco, CA. The company specializes in developing monoclonal antibodies. On Jan. 8, Wyeth reached an agreement with Catalyst Biosciences, also of South San Francisco, CA, to develop treatments for cancer and metabolic diseases. Catalyst could receive as much as $100 million, excluding royalties based on product sales resulting from the deal.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union